Gilead announces European Medicines Agency validation for lenacapavir
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Targeted Oncology2h
FDA Accepts Odronextamab BLA in Relapsed/Refractory Follicular Lymphoma
The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...
Drug companies and Minister agree medicines need to be available to patients more quickly
Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...
The Lancet46m
Trastuzumab rezetecan, a new antibody–drug conjugate in HER2-mutated NSCLC
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
Business Wire2d
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
Pharmabiz1d
EMA validates Gilead’s MAA and EU-Medicines for all application for twice-yearly lenacapavir for HIV prevention
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
Daily3d
Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...
PharmiWeb5d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
European study highlights inequalities in diagnosis and treatment of biliary tract cancer
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
PipelineReview.com6d
Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites
MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific ...
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...